In order to gain information on the activity shown by alpha-peptide/beta-sulfonamidopeptide hybrid analogs of the potent chemotactic agent fMLF-OMe, a structure-activity study is reported on N-Boc- and N-formyl tripeptide models containing an aminoalkanesulfonic acid as central residue. Directed migration (chemotaxis), superoxide anion production, and lysozyme release have been measured. The biochemical functions and the conformational properties of the new compounds are discussed and related to previously studied models containing beta-residues.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2005.11.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MCP5, a methyl-accepting chemotaxis protein regulated by both the Hk1-Rrp1 and Rrp2-RpoN-RpoS pathways, is required for the immune evasion of Borrelia burgdorferi.
PLoS Pathog
December 2024
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Borrelia (or Borreliella) burgdorferi, the causative agent of Lyme disease, is a motile and invasive zoonotic pathogen adept at navigating between its arthropod vector and mammalian host. While motility and chemotaxis are well known to be essential for its enzootic cycle, the role of each methyl-accepting chemotaxis proteins (MCPs) in the infectious cycle of B. burgdorferi remains unclear.
View Article and Find Full Text PDFImmunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3.
Biomedicines
December 2024
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies.
View Article and Find Full Text PDFDelivery of small interfering RNA by hydrogen sulfide-releasing nanomotor for the treatment of Parkinson's disease.
J Control Release
January 2025
National and Local Joint Engineering Research Center of Biomedical Functional Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China; Institute for Life and Health, Nanjing Drum Tower Hospital, Nanjing Normal University, Nanjing 210023, China. Electronic address:
Article Synopsis
- Small interfering RNA (siRNA) shows promise for treating Parkinson's disease by inhibiting the formation of harmful α-synuclein aggregates, but challenges like low stability and difficulty crossing the blood-brain barrier limit their effectiveness.
- Researchers created an HS donor nanomotor that encapsulates siRNA, protecting its activity and targeting it to damaged mitochondria in neurons, enhancing therapeutic outcomes.
- The nanomotor combines two specific polymers to cross the blood-brain barrier and specifically target damaged cells, allowing it to silence the α-syn gene and degrade existing aggregates, which could potentially reverse Parkinson's disease pathology.
Enzymatic nanomotors with chemotaxis for product-based cancer therapy.
J Control Release
January 2025
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Electronic address:
The development of an intelligent nanomotor system holds great promise for enhancing the efficiency and effectiveness of antitumor therapy. Leveraging the overexpressed substances in the tumor microenvironment as propellants and chemotactic factors for enzyme-powered nanomotors represents a versatile and compelling approach. Herein, a plasma amine oxidase (PAO)-based chemotactic nanomotor system has been successfully developed, with the ability to enzymatically produce toxic acrolein and HO from the upregulated polyamines (PAs) in the tumor microenvironment for active tumor therapy.
View Article and Find Full Text PDFProtection of beta cells against cytokine-induced apoptosis by the gut microbial metabolite butyrate.
FEBS J
January 2025
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Type 1 diabetes (T1D) is characterized by immune cell infiltration in the islets of Langerhans, leading to the destruction of insulin-producing beta cells. This destruction is driven by secreted cytokines and cytotoxic T cells inducing apoptosis in beta cells. Butyrate, a metabolite produced by the gut microbiota, has been shown to have various health benefits, including anti-inflammatory and anti-diabetic effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!